9 research outputs found
Design Acculturation and Design Didactics
No full textThis paper is based on the investigation of specializing and professionalizing training experiences analyzed by the author, and a case study about the origin of a "connection" between acculturation, skills improvement and the evolution of the design profession.
The main topics covered by the discussion concern the expansion and growth of the design discipline on the one hand, and on the other hand the issue of tools and methods of a training that needs to keep up with the times and with the change of project technologies , but still following and supporting the same continuous extension of the limits of the discipline.
It is precisely the issue of the criticality and complexity of the limits that this paper intends to explain with a perspective that arises from the education users and is detected through their learning requests, their identification of the main topics for specialization and their ability to understand the relationship between the topics of a constantly evolving discipline and the professional skills to be acquired and proposed on the market of intellectual professions.
Each school, which generates an offer aimed at the implementation of skills and cultural depth, acts as a connector between limit knowledge and its application in a professional context in which designers are increasingly "integrators" and fewer individual authors. This position has been highlighting for some time the complexity of offering educational quality in the fluidity of the context and we can generally see today the diffusion of digital solution and for the digital, with some experimentation about distance learning. However, the learning-by-doing method remains widespread, although perhaps challenged by the substantial change in the project discipline. The pandemic has introduced constraints that have forced methods and approaches to design teaching, creating significant opportunities for experimentation, which we are going to discuss
Análisis de Prestación de Particle Swarm Optimization aplicado a Categorización no Supervisada de Textos Cortos
No full text[ES] Existe actualmente la necesidad de acceder a información en línea tal
como resúmenes, noticias, opiniones, evaluaciones de productos, etc. Dicha información está disponible en la web, generalmente con el formato de textos cortos. Trabajos previos han demostrado la efectividad de un algoritmo discreto Particle Swarm
Optimization, llamado CLUDIPSO, para el agrupamiento de colecciones pequeñas
de textos cortos. Este artículo presenta un estudio preliminar sobre la prestación
de CLUDIPSO con colecciones más grandes. Los resultados fueron comparados con
los obtenidos con algoritmos representativos del estado del arte en el área. El trabajo experimental muestra una fuerte evidencia sobre los inconvenientes que posee
el algoritmo cuando debe agrupar colecciones de mayor tamaño. Con respecto a
este último aspecto, se discuten posibles razones del comportamiento inadecuado de
CLUDIPSO y se consideran algunas alternativas para resolver los problemas observados.[EN] Nowadays there is a need to access to on line information such as abstracts, news, opinions, evaluations of products, etc. That information is generally
available on the web as short texts. Previous works have demonstrated the e¿ectiveness of a discrete Particle Swarm Optimization algorithm, named CLUDIPSO, for
clustering small short-text corpora. This article presents a preliminary study about
the performance of CLUDIPSO on larger short-text corpora. The results were compared with those of the most representative algorithms of the state-of-the-art in the
area. The experimental work gives strong evidence about the drawbacks of this
algorithm to manage larger corpora. With respect to this last aspect, some possible
reasons about the poor behavior of CLUDIPSO with larger short texts corpora are
discussed and some alternatives in order to solve the problems observed, are considered.This research work was done in the framework of Marie Curie actions PEOPLE-IRSES 269180 WiQ-Ei: Web information Quality Evaluation initiative. The work of the first author is partially funded by the UPV program PAID-02-10-2257. The work of
the last two authors is partially funded by the MICINN research project TEXTENTERPRISE 2.0 TIN2009-13391-C04-03
(Plan I+D+i). The fourth author belongs to the VLC/CAMPUS Microcluster on Multimodal Interaction in Intelligent Systems.Cagnina, LC.; Ingaramo, DA.; Errecalde, ML.; Rosso, P. (2011). Performance analysis of Particle Swarm Optimization applied to Unsupervised Categorization of Short Texts. Procesamiento del Lenguaje Natural. 47:207-214. https://riunet.upv.es/handle/10251/28834S2072144
Políticas públicas, Género y Derechos Humanos en América Latin
No full textper K.Lauritsen, released for public access. June 4, 2019. ac.El enfoque de género ha producido verdaderas transformaciones tanto a nivel del conocimiento en las ciencias sociales, incorporando nuevos temas y problemas a partir de la teoría feminista, como a nivel de las acciones de polí
Las islas rocosas del Paraje Tres Cerros: un refugio de biodiversidad en el litoral mesopotámico argentino
No full textEn este artículo difundimos nuestro conocimiento sobre la naturaleza de un paisaje único del litoral mesopotámico argentino, el Paraje Tres Cerros, con el objetivo de valorizar y promover la conservación de la biodiversidad en este sitio. Divulgamos los principales resultados del proyecto de relevamiento y conservación de la fauna de vertebrados, llevado a cabo en el área en los últimos tres años. Finalmente discutimos la problemática originada por los intentos fallidos de creación de una reserva natural en este sitio y brindamos los lineamientos futuros a seguir para lograr la creación de un área de conservación.Fil: Cajade, Rodrigo. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Medina, Walter Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Nordeste. Instituto de Botánica del Nordeste (i); Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Salas, Roberto Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Nordeste. Instituto de Botánica del Nordeste (i); Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Fandiño, Blas. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; Argentina. Escuela Nro. 3163 “IDEI PILARES”; ArgentinaFil: Paracampo, Ariel Hernán. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Instituto de Limnología "Dr. Raul A. Ringuelet"; ArgentinaFil: Garcia, Ignacio Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico la Plata. Instituto de Limnología "dr. Raul A. Ringuelet"; ArgentinaFil: Pautasso, Andres. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; Argentina. Museo Provincial de Ciencias Naturales Florentino Ameghino; ArgentinaFil: Piñeiro, Jose Miguel. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Acosta, José Luis. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Zaracho, Victor Hugo. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Avalos, Adan Alberto. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Gomez, Fernando. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Odriozola, Mariana Paola. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Ingaramo, María del Rosario. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Contreras, Félix Ignacio. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; Argentina. Universidad Nacional del Nordeste. Instituto de Investigaciones Geohistóricas; ArgentinaFil: Rivolta, Matías Daniel. Municipalidad de La Cruz; ArgentinaFil: Hernando, Alejandra Beatriz. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; ArgentinaFil: Álvarez, Blanca Beatriz. Universidad Nacional del Nordeste. Facultad de Cs.exactas Naturales y Agrimensura. Departamento de Biologia. Laboratorio de Herpetologia; Argentina. Alianza para la Conservación del Patrimonio Natural y Cultural del Paraje Tres Cerros; Argentin
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND):a double-blind, randomised placebo-controlled trial
No full textBackground: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A 1c (HbA 1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major adverse cardiovascular events when added to the existing antihyperglycaemic regimens of individuals with type 2 diabetes with and without previous cardiovascular disease and a wide range of glycaemic control.Methods: This multicentre, randomised, double-blind, placebo-controlled trial was done at 371 sites in 24 countries. Men and women aged at least 50 years with type 2 diabetes who had either a previous cardiovascular event or cardiovascular risk factors were randomly assigned (1:1) to either weekly subcutaneous injection of dulaglutide (1·5 mg) or placebo. Randomisation was done by a computer-generated random code with stratification by site. All investigators and participants were masked to treatment assignment. Participants were followed up at least every 6 months for incident cardiovascular and other serious clinical outcomes. The primary outcome was the first occurrence of the composite endpoint of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (including unknown causes), which was assessed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01394952.Findings: Between Aug 18, 2011, and Aug 14, 2013, 9901 participants (mean age 66·2 years [SD 6·5], median HbA 1c 7·2% [IQR 6·6–8·1], 4589 [46·3%] women) were enrolled and randomly assigned to receive dulaglutide (n=4949) or placebo (n=4952). During a median follow-up of 5·4 years (IQR 5·1–5·9), the primary composite outcome occurred in 594 (12·0%) participants at an incidence rate of 2·4 per 100 person-years in the dulaglutide group and in 663 (13·4%) participants at an incidence rate of 2·7 per 100 person-years in the placebo group (hazard ratio [HR] 0·88, 95% CI 0·79–0·99; p=0·026). All-cause mortality did not differ between groups (536 [10·8%] in the dulaglutide group vs 592 [12·0%] in the placebo group; HR 0·90, 95% CI 0·80–1·01; p=0·067). 2347 (47·4%) participants assigned to dulaglutide reported a gastrointestinal adverse event during follow-up compared with 1687 (34·1%) participants assigned to placebo (p<0·0001).Interpretation: Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.</p
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
No full textInternational audienceBACKGROUND:Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.METHODS:This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.FINDINGS:Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).INTERPRETATION:Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
No full textBackground Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. Methods This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0.90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2.5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants. Findings Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0.72, 95% CI 0.57-0.90, p=0.0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0.54 95% CI 0.35-0.82, p=0.0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0.86, 95% CI 0.69-1.08, p=0.19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0.67, 95% CI 0.45-1.00, p=0.05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1.61, 95% CI 1.12-2.31, p=0.0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1.68, 95% CI 1.17-2.40; p=0.0043). Interpretation Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding.peer-reviewe
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
No full textGARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide
No full textBackground: The Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) is a worldwide non-interventional study of stroke prevention in patients with non-valvular AF. Methods and results: 52,080 patients with newly diagnosed AF were prospectively enrolled from 2010 to 2016. 4121 (7.9%) of these patients were recruited in DACH [Germany (n = 3567), Austria (n = 465) and Switzerland (n = 89) combined], and 47,959 patients were from 32 countries in other regions worldwide (ORW). Hypertension was most prevalent in DACH and ORW (85.3% and 75.6%, respectively). Diabetes, hypercholesterolaemia, carotid occlusive disease and vascular disease were more prevalent in DACH patients vs ORW (27.6%, 49.4%, 5.8% and 29.0% vs 21.7%, 40.9%, 2.8% and 24.5%). The use of non-vitamin K antagonist oral anticoagulants (NOACs) increased more in DACH over time. Management of vitamin K antagonists was suboptimal in DACH and ORW (time in therapeutic range of INR ≥ 65% in 44.6% and 44.4% of patients or ≥ 70% in 36.9% and 36.0% of patients, respectively). Adjusted rates of cardiovascular mortality and MI/ACS were higher in DACH while non-haemorrhagic stroke/systemic embolism was lower after 2-year follow-up. Conclusions: Similarities and dissimilarities in AF management and clinical outcomes are seen in DACH and ORW. The increased use of NOAC was associated with a mismatch of risk-adapted anticoagulation (over-and-undertreatment) in DACH. Suboptimal control of INR requires educational activities in both regional groups. Higher rates of cardiovascular death in DACH may reflect the higher risk profile of these patients and lower rates of non-haemorrhagic stroke could be associated with increased NOAC use. Graphical abstract: [Figure not available: see fulltext.]
